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Objectives. The 3-year survival rates of 500 patients with
congestive heart failure (CHF) referred for heart transplantation
were assessed to evaluate the clinical and exercise variables most
useful for estimating prognostic risk.
Background. Detailed prognostic risk stratification of patients
with a peak exercise oxygen consumption (VO2) <214 ml/min per kg
to identify lower risk patient subsets has been limited in earlier
series by relatively small sample size.
Methods. Cardiopulmonary exercise testing was performed in
500 patients with CHF referred for heart transplantation; 154
(31%) had a peak exercise VO2 <214 ml/min per kg. Univariate and
multivariate analyses were performed to identify the 3-year prog-
nostic risk.
Results. The 55% 3-year survival rate of the 77 patients with a
peak exercise VO2 <214 ml/min per kg unable to reach a peak
exercise systolic blood pressure (SBP) of 120 mm Hg was signif-
icantly lower than the 83% survival rate in the 74 patients able to
reach this exercise blood pressure (p 5 0.004). Multivariate
analysis revealed that peak exercise SBP (p 5 0.0005) and percent
predicted peak VO2 <250% (p 5 0.04) were the two most important
predictors for the combined end point of death or listing as
Status 1.
Conclusions. Peak exercise SBP and percent predicted peak
exercise VO2 are two inexpensive and easily measured noninvasive
variables that can be used to further prognostically risk stratify
ambulatory patients with CHF referred for heart transplantation
with a peak exercise VO2 <214 ml/min per kg.
(J Am Coll Cardiol 1998;31:577–82)
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The decision to list ambulatory patients with congestive heart
failure (CHF) for heart transplantation is difficult, and objec-
tive measurements for identifying patients most likely to
benefit from the procedure are highly desirable. In a recent
American Heart Association consensus document, clinical,
hemodynamic, functional capacity, neurohumoral and arrhyth-
mia variables were defined to optimize evaluation, treatment
and selection of candidates for heart transplantation (1).
Exercise testing with respiratory gas analyses is a standardized
approach for objectively documenting functional capacity and
is a more reliable measurement than exercise duration (2).
Mancini et al. (3), Stelken et al. (4) and others (5–8) in
observational reports have demonstrated that the short-term
prognosis of patients with a peak oxygen consumption (VO2)
#14 ml/min per kg is markedly impaired (5–8) compared with
heart transplant recipients followed up for a similar duration
(3,4).
Exercise capacity is determined in part by the ability to
increase cardiac output and extract oxygen peripherally and by
muscle conditioning, motivation, age, gender and pulmonary
status. The multifactorial control of variables that influence
peak exercise capacity may explain in part why some patients
with CHF and limited exercise capacity (peak exercise VO2
#14 ml/min per kg) have a favorable prognosis and may be
treated with continued medical therapy rather than heart
transplantation (9–17). Stevenson et al. (10) reported the
outcome of 68 of 107 patients listed for heart transplantation
with an initial peak VO2 #14 ml/min per kg. After 6 months of
optimizing medical management, 38 patients increased peak
VO2, and 31 were taken off the active waiting list; their
subsequent 2-year survival rate was 100%. Thus, in addition to
the standard variables used to estimate prognosis in patients
with CHF, such as duration of symptoms, presence of obstruc-
tive coronary disease, New York Heart Association functional
class, pulmonary artery systolic pressure and gender, additional
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criteria to optimally select the highest risk patients with a peak
exercise VO2 #14 ml/min per kg would be of benefit. In many
earlier reports (3–7), the number of patients with a peak VO2
#14 ml/min per kg was insufficient to study this particular
subset in detail. The aim of the present report is to examine the
use of cardiopulmonary exercise testing in risk stratification of
500 patients with CHF referred for heart transplantation
evaluation. Specifically, we tested the hypothesis that clinical
variables, exercise hemodynamic response and adjustment of
peak VO2 for age, gender and weight would optimize mortality
estimates in the ;30% of patients with CHF and a peak VO2
#14 ml/min per kg referred for heart transplantation evalua-
tion.
Methods
Patients. The study included 500 consecutive ambulatory
patients with CHF referred to the Saint Louis University Heart
Failure Service and who performed cardiopulmonary exercise
testing between March 1991 and April 1996. The consecutive
series includes 176 patients previously described (4). The mean
(6SD) age was 50 6 10 years (range 19 to 80); 79% were men,
and most patients were in functional class III. The etiology of
heart failure was ischemic heart disease in 238 patients and
dilated cardiomyopathy in 262. At the time of initial evalua-
tion, 114 patients (23%) were listed for heart transplantation,
and 72 (14%) ultimately underwent heart transplantation
during follow-up. Of the 500 patients, 154 (31%) had a peak
exercise VO2 #14 ml/min per kg; their clinical characteristics
are shown in Table 1.
Cardiopulmonary exercise testing. A symptom-limited car-
diopulmonary exercise test was performed after written in-
formed consent was obtained. The modified Bruce protocol
was used in 185 patients (37%) and the Asymptomatic Cardiac
Ischemia Pilot (ACIP) or modified Naughton protocol in 315
(63%) (18). Heart rate, blood pressure and a 12-lead electro-
cardiogram were obtained at rest, at each exercise stage and
for 5 min in the postexercise phase. Respiratory gas analysis
was measured using a Medical Graphics System, as previously
described (4). Oxygen consumption (VO2), carbon dioxide
production (VCO2), minute ventilation (VE), breathing rate,
respiratory rate exchange ratio and ventilatory equivalents for
O2 (VE/VO2) and CO2 (VE/VCO2) were measured continuously
using a moving average for eight breaths. Peak VO2 was
defined as the highest VO2 observed during the exercise test.
Age-, gender- and weight-adjusted predicted VO2 values were
determined using the Wassermann formulas (19). The anaer-
Abbreviations and Acronyms
CHF 5 congestive heart failure
SBP 5 systolic blood pressure
VE 5 minute ventilation
VCO2 5 carbon dioxide production
VO2 5 oxygen consumption
Table 1. Clinical and Exercise Characteristics of 154 Patients With Marked Impairment of Exercise
Capacity (peak oxygen uptake #14 ml/min per kg)
Total Survivors Nonsurvivors p Value
Age (yr) 52 6 11 53 6 11 50 6 12 0.23
Male 75% 72% 83% 0.1
Ischemic cardiomyopathy 55% 56% 46% 0.87
Hypertension 45% 49% 31% 0.06
Diabetes mellitus 20% 21% 17% 0.38
Smoking 49% 48% 63% 0.6
ACE inhibitor therapy 87% 86% 91% 0.37
Digitalis usage 73% 70% 86% 0.06
Diuretic usage 82% 79% 94% 0.04
Mean LVEF (%) (n 5 57) 24 6 9 24 6 10 23 6 8 0.5
Exercise variables
Rest HR (beats/min) 95 6 17 94 6 17 98 6 16 0.17
Peak exercise HR (beats/min) 130 6 21 131 6 22 129 6 19 0.7
Peak rest HR (beats/min) 35 6 18 54 6 24 37 6 20 0.001
Peak exercise SBP (mm Hg) 127 6 30 131 6 30 114 6 25 0.002
Peak exercise RER 1.11 6 0.2 1.15 6 0.2 1.15 6 0.16 0.26
Peak VE (liters/min) 51 6 18 49 6 19 56 6 17 0.05
MVV (liters/min) 97 6 32 95 6 32 104 6 31 0.12
Peak VO2 (ml/min per kg) 12 6 2 11.5 6 1.9 11.5 6 1.8 0.97
% predicted peak VO2 44 6 16 45 6 17 39 6 11 0.04
Anaerobic threshold
(ml/min per kg) (n 5 350)
9 6 1 9 6 1 9 6 2 0.81
Data presented are mean value 6 SD or percent of patients. ACE 5 angiotensin converting enzyme; HR 5 heart
rate; LVEF 5 left ventricular ejection fraction by contrast left ventriculography; MVV 5 maximal ventilatory volume;
RER 5 respiratory exchange ratio; SBP 5 systolic blood pressure; VE 5 minute ventilation; VO2 5 oxygen consumption.
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obic threshold was determined in the last consecutive 350
patients using the V-slope method (20). Of the 500 patients,
422 (84%) stopped exercise because of either dyspnea or
excessive fatigue.
Follow-up. All patients were followed-up prospectively at
the Saint Louis University Heart Failure clinic. The average
duration of follow-up was 25 6 17 months (range 0.2 to 64.5).
Cardiac end points were defined as death or admission to the
intensive care unit for prolonged inotropic or mechanical
cardiovascular support, leading to Status 1 listing for heart
transplantation. During follow-up, 56 patients died, and 72
patients underwent heart transplantation.
Statistical analysis. Univariate analysis of baseline clinical
and exercise variables was performed for the end point of
death or cardiac event (death or change to Status 1 transplant
priority). Results are expressed as mean value 6 SD. Inter-
group differences between clinical or exercise variables were
compared using an unpaired t test or chi-square analysis, where
appropriate. To account for multiple subgroup comparisons,
p 5 0.01 was regarded as showing some evidence against the
null hypothesis and p 5 0.001 as strong evidence.
Survival estimates were calculated using the Kaplan-Meier
method (21). Differences between survival estimates were
compared using the log-rank test (22). Cox proportional
hazard analyses were used to measure the impact of clinical
history and cardiopulmonary exercise test results on cardiac
events (23). Separate analyses were performed for the end
point of death or cardiac event (death or change to Status 1
transplant priority).
Results
The average peak VO2 of the study group was 17.3 6
5.7 ml/min per kg (60.7 6 21.6% predicted peak VO2). Of the
500 patients, 34, 120 and 346 reached a peak VO2 #10, .10 to
14 and .14 ml/min per kg, respectively. Univariate predictors
of mortality included a greater rest heart rate (p 5 0.0008) and
a lower peak exercise heart rate (p 5 0.01), SBP (p , 0.0001),
peak exercise VO2 (p , 0.0001), percent predicted VO2 (p ,
0.0001) and anaerobic threshold (p , 0.0001).
Independent predictors of death by multivariate analysis
were peak VO2 #14 ml/min per kg (p , 0.0001), peak exercise
SBP #120 mm Hg (p , 0.0001), rest heart rate .100 beats/
min (p 5 0.03) and male gender (p 5 0.003). When multivar-
iate analysis was performed for the combined end point of
death or listing as Status 1, peak exercise VO2 #14 ml/min per
kg (p 5 0.002), peak SBP #120 mm Hg (p , 0.0001) and rest
heart rate .100 beats/min (p , 0.0001) were selected as
independent predictors.
Patients with marked impairment of exercise capacity
(peak exercise VO2 <14 ml/min per kg). Clinical and exercise
variables to predict death were examined by univariate analysis
in the 154 patients with a peak VO2 #14 ml/min per kg (Table
1). Peak exercise SBP ,120 mm Hg (p 5 0.002) was the only
variable that was a significant predictor of death. Peak exercise
SBP (p 5 0.004), percent predicted peak VO2 (p 5 0.002),
male gender (p 5 0.02) and rest heart rate (p 5 0.03) were the
only significant univariate predictors of the combined end
point of death or change to Status 1 transplant priority.
Multivariate analysis revealed that peak exercise SBP was
the single most important variable for death (p 5 0.0005), and
for the combined end point, peak exercise SBP (p 5 0.0005)
and percent predicted peak VO2 #50% (p 5 0.04) were the
only two variables selected (Table 2).
Three-year survival estimates. The 3-year survival rate was
93 6 2%, 68 6 5% and 75 6 9% for patients with a peak VO2
.14, .10 to 14 and #10 ml/min per kg, respectively (Fig. 1).
The difference between patients with a peak VO2 .14 and
#14 ml/min per kg was statistically significant (p , 0.0001).
There was no significant difference between patients in whom
peak exercise capacity was .10 to 14 and #10 ml/min per kg.
When patients were stratified according to percent pre-
dicted peak VO2, the 3-year survival rate was 93 6 2%, 77 6
5% and 57 6 10%, respectively (Fig. 2). The difference
between patients who achieved a percent predicted peak VO2
.50%, .35% to 50% and #35% was statistically significant
(p , 0.0001).
The 154 patients with a peak exercise VO2 #14 ml/min per
kg were stratified according to percent predicted peak VO2
.50% (n 5 44), and #50% (n 5 110) (Fig. 3). The 91 6 5%
3-year survival rate of patients with a peak VO2 #14 ml/min per
kg able to achieve a percent predicted peak VO2 .50% was
Table 2. Multivariate Analysis for End Point of Death or End Point
of Death or Listing as Status 1 in 154 Patients With a Peak Oxygen
Uptake #14 ml/min per kg









Peak SBP ,120 mm Hg 0.0005 12.4 0.0005 11.4
% predicted peak VO2
#50 ml/min per kg
0.02 5.6 0.04 4.6
Abbreviations as in Table 1.
Figure 1. The 3-year survival rate was 93 6 2%, 68 6 5% and 75 6 9%
for patients with a peak VO2 .14, .10 to 14 and #10 ml/min per kg,
respectively. The difference in patients with a VO2 #10 and .10 to
14 ml/min per kg was not statistically significant.
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similar to the 93 6 2% survival rate of patients initially able to
achieve a peak exercise VO2 .14 ml/min per kg. However, the
61 6 5% 3-year survival rate in patients with a peak exercise
VO2 #14 ml/min per kg and a percent predicted peak VO2
#50% was associated with a significantly worse 3-year survival
rate (p 5 0.0009). The results were similar for the combined
end point of cardiac death or listing as Status 1.
Exercise SBP. The 3-year survival estimates of patients
with a peak VO2 #14 ml/min per kg were examined in patients
able to reach a peak exercise SBP .120 mm Hg and
#120 mm Hg (Fig. 4). In patients with a peak VO2 #14 ml/min
per kg, the 55% 3-year survival rate of the 77 patients unable
to reach a peak exercise SBP of 120 mm Hg was significantly
worse than the 83% survival rate in the 74 patients able to
reach this exercise SBP (p 5 0.004). Exercise SBP measure-
ments were not available for three patients. The 83% 3-year
survival rate in patients with a peak VO2 #14 ml/min per kg
and a peak exercise SBP .120 mm Hg was significantly lower
than that of the 346 patients with a peak VO2 .14 ml/min per
kg (p 5 0.02).
Gender. In the 346 patients with a peak VO2 .14 ml/min
per kg, the 3-year survival rate was 100% in women and 92 6
2% in men (p 5 0.07). The 3-year survival rate in the 154
patients with a peak VO2 #14 ml/min per kg was 82 6 7% in
women and 65 6 6% in men (p 5 0.08).
Univariate and multivariate analyses of the 105 women in
the study cohort revealed that the percent predicted peak VO2
was the best independent predictor of survival free of cardiac
events. However, the number of events was relatively small;
seven women died before heart transplantation, and an addi-
tional four patients were listed as Status 1.
Of the 44 patients with a peak VO2 #14 ml/min per kg with
a percent predicted peak VO2 .50% (Fig. 3), 32 were women
(73%). Of the 110 patients with a peak VO2 #14 ml/min per kg
with a percent predicted peak VO2 #50%, 7 were women (6%)
(p , 0.001). There were no significant gender differences with
regard to age.
Discussion
The use of cardiopulmonary exercise testing as an objective
measure for estimating prognosis in ambulatory patients with
CHF is well established (1–8). The prognostic risk significantly
increases when the peak VO2 decreases to ,14 ml/min per kg.
In our 154 patients with a peak VO2 #14 ml/min per kg, we did
not find a significant difference in 3-year survival rates between
patients with a peak VO2 .10 to 14 and #10 ml/min per kg,
confirming the findings of Mancini et al. (3). The 93% 3-year
survival rate in our 346 patients with a peak exercise VO2
.14 ml/min per kg is consistent with earlier reports (3–8).
Chomsky et al. (15) evaluated cardiopulmonary and hemo-
dynamic exercise responses of 185 ambulatory patients with
CHF and a mean peak VO2 of 12.9 ml/min per kg referred for
Figure 2. The 3-year survival rate was 93 6 2%, 77 6 5% and 57 6
10% in patients with a percent predicted (Pred.) peak VO2 .50%,
.35% to 50% and #35%, respectively. The difference between each
group was significant at p , 0.0001.
Figure 3. The 3-year survival of patients with a peak VO2 #14 ml/min
per kg is stratified according to percent predicted (Pred.) peak VO2
.50% or #50%. The 91 6 5% of the 44 patients with a percent
predicted VO2 .50% was significantly greater than the 61 6 5% of the
110 patients with a peak VO2 #50% (p 5 0.0009).
Figure 4. The 3-year survival rate in the 154 patients with a peak VO2
#14 ml/min per kg was 83 6 4% and 55 6 3% in patients with a peak
exercise SBP .120 and #120 mm Hg (p 5 0.004). The difference
between patients with a peak VO2 .14 ml/min per kg and those with
a peak VO2 #14 ml/min per kg and a peak exercise SBP .120 mm Hg
was significant (p 5 0.02).
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heart transplantation. The 1-year survival estimates were sig-
nificantly improved by measuring exercise cardiac output
rather than peak exercise VO2 alone. In multivariate analysis, a
peak exercise VO2 ,10 ml/min per kg identified a high risk
patient subset. Mancini et al. (14), in a 65 patient series with a
mean peak VO2 of 12.1 ml/min per kg, reported only a minimal
improvement in risk prognostication when exercise cardiac
output measurements were added to noninvasive cardiopul-
monary exercise testing after an average follow-up of 232
days. The addition of right heart catheterization to cardio-
pulmonary exercise testing when evaluating ambulatory
patients with CHF increases costs and exposes the patient to
a minor risk. If similar results can be achieved by adjusting
peak VO2 measurements for age, gender and weight and
assessment of peak exercise SBP, it would be a more
cost-effective approach. Our study differs from the earlier
reports in that exercise hemodynamic measurements were
not made, and the duration of follow-up was 3 years rather
than 1 year. The average peak VO2 in our 154 patients with
a peak VO2 #14 ml/min per kg was 12 6 2 ml/min per kg,
similar to the patients studied by Chomsky et al. (15) and
Mancini et al. (14).
In our patients with a peak VO2 #14 ml/min per kg, peak
exercise SBP and percent predicted peak VO2 were important
variables useful in further stratifying prognostic risk. The data
indicate that in patients with a peak VO2 #14 ml/min per kg,
the ability to achieve a predicted peak VO2 .50% is
associated with a 3-year survival rate similar to patients able
to achieve a peak VO2 .14 ml/min per kg (15). The 3-year
survival rate of 61 6 6% in patients unable to reach 50%
predicted peak VO2 identified a patient subset, predomi-
nantly male, in whom heart transplantation would be ex-
pected to result in an improved survival benefit. In the
subset of patients with a peak VO2 #14 ml/min per kg,
inability to achieve a peak exercise SBP of 120 mm Hg also
identified a prognostic high risk patient subset with an
unfavorable 3-year survival rate (55 6 7%). The cutpoint of
120 mm Hg for exercise SBP was chosen because the
average exercise SBP in patients with a peak VO2
,14 ml/min per kg was 124 mm Hg in our series. The
relation between the inability to adequately augment exer-
cise SBP and an adverse prognosis has been reported by
others, although in some series peak exercise SBP has not
been found to be predictive of mortality (8,24,25).
In a previous report from our laboratory (4), percent
predicted peak VO2 was found to be a more useful predictor of
1-year outcome than peak VO2 alone. In the earlier report, the
average peak VO2 was 16.3 ml/min per kg in the 181 patients
with CHF, in contrast to the 17.3 ml/min per kg in our current
500-patient series with a longer duration of follow-up. These
differences may explain in part why percent predicted peak
VO2 was predictive of outcome only in the subset of patients in
our current series with a peak VO2 ,14 ml/min per kg. We
chose the Wassermann formula to derive the percent predicted
VO2 in both reports; other equations can also be used to derive
this variable (4). Osada et al. (26) reported that the greatest
magnitude of increase in peak VO2 after heart transplant is in
a subset of patients with the lowest preoperative percent
predicted peak VO2. Aaronson and Mancini (11) examined
percent predicted maximal VO2 and peak exercise consump-
tion in 272 ambulatory patients with CHF referred for heart
transplantation. The performance of peak exercise VO2 uncor-
rected for body weight was similar to that of weight-normalized
peak VO2. In univariate hazard analysis, percent predicted VO2
with the Wassermann formula was the single best predictor of
patient survival, with the predominant improvement in survival
estimates occurring in women. Adams et al. (27) reported a
significantly better survival rate in women than in men with
symptomatic heart failure and nonischemic cardiomyopathy.
In the present report, sample size precluded a detailed analysis
of gender differences because of the relatively small number of
events in women.
Study limitations. The present cross-sectional study in-
cluded 154 patients with a peak VO2 #14 ml/min per kg. There
were only 34 patients with a peak exercise VO2 #10 ml/min per
kg, limiting the ability to study predictors of mortality in the
latter patient subset. Many such patients have significant
dyspnea during exercise, making it difficult to measure venti-
latory gas variables with a mouthpiece or face mask. In some
earlier reports, bicycle ergometry was used to measure peak
VO2 rather than treadmill exercise, as was used in the present
study. Peak VO2 with treadmill exercise is usually greater than
that achieved with bicycle ergometry. Therefore, our results
cannot be strictly compared with studies in which bicycle
ergometry was used.
We chose a cutpoint of 120 mm Hg to assess exercise SBP
as a predictor of mortality. The measurement was made by
sphygmomanometry, not central arterial measurements. Peak
SBP measurements during exercise are also influenced by
technique and sampling frequency. Vasodilator drug therapy
may also limit exercise SBP response. In the present retrospec-
tive report, we were not able to measure all antihypertensive
drug therapy at the time of exercise testing. Exercise capacity
can be significantly improved by participation in a cardiac
rehabilitation program. We did not monitor compliance or
physical activity, such as walking and cycling, or other leisure
time and occupational activity in follow-up and thus cannot
assess the impact of sedentary versus exercise activities on
exercise test performance.
Conclusions. Our findings confirm and extend previous
observations that cardiopulmonary exercise testing is useful
in estimating prognostic risk in patients with CHF and re-
fine the cardiopulmonary test indications for heart transplan-
tation. In particular, in patients with a peak exercise VO2
#14 ml/min per kg, the inability to increase exercise SBP to
.120 mm Hg is a powerful predictor of subsequent mortality,
and percent predicted peak VO2 #50% is an important pre-
dictor of cardiac events, particularly subsequent cardiac dete-
rioration leading to hospital admission and listing as Status 1
transplant priority.
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